Trends in haematopoietic cell transplantation for inborn errors of metabolism
The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Summary: For the last 25 years, haematopoietic cell transplantation (HCT) has been used as effective therapy for selected inborn errors of metabolism (IEMs), mainly lysosomal storage diseases and peroxisomal disorders. The main rational for HCT in IEMs is based on the provision of correcting enzymes by donor cells within and outside the blood compartment. The ultimate goal of HCT is to achieve a normal or near‐normal life and normal neurodevelopment. HCT has been performed for more than 20 diseases. Only for Hurler syndrome, X‐ALD and infantile Krabbe disease, are detailed studies available suggesting that HCT is indicated for carefully selected cases. Improvement of transplantation techniques and alternative therapies may change the recommended (contra‐)indications for IEM. A recent example of emerging transplantation techniques is the fast availability of unrelated cord blood (UCB). UCB makes HCT feasible in patients with rapidly progressive neurological diseases. Because of the fast availability of UCB and therefore the ability to transplant shortly after diagnosis, there is no indication for patients in a moderate/good clinical condition to receive enzyme replacement therapy (ERT; in Hurler syndrome) prior to or during HCT and can ERT only be considered in patients with poor clinical condition. Mesenchymal stem cell infusions with HCT is an emerging technique, and might be interesting in halting the remaining defects after successful HCT. Improvement in HCT techniques and novel stem cell sources will significantly impact the safety and efficacy of this therapy as well as expand the list of candidate disorders. A good functioning worldwide registry would be necessary to measure the effects of the procedures performed in more detail.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Le Blanc, K., Rasmusson, I., Sundberg, B., Götherström, C., Hassan, M., Uzunel, M., & Ringdén, O. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16104-7 · Cited by 2,734
Moser, H. W., Mahmood, A., & Raymond, G. V. (2007) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0421 · Cited by 663
Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy
Moser, H. (1997) · Brain · doi:10.1093/brain/120.8.1485 · Cited by 478
Peters, C., Charnas, L. R., Tan, Y., Ziegler, R. S., Shapiro, E. G., DeFor, T., Grewal, S. S., Orchard, P. J., Abel, S. L., Goldman, A. I., et al. (2004) · Blood · doi:10.1182/blood-2003-10-3402 · Cited by 374
Aubourg, P., Blanche, S., Jambaqué, I., Rocchiccioli, F., Kalifa, G., Naud-Saudreau, C., Rolland, M.-O., Debré, M., Chaussain, J.-L., Griscelli, C., et al. (1990) · New England Journal of Medicine · doi:10.1056/nejm199006283222607 · Cited by 366
Shapiro, E., Krivit, W., Lockman, L., Jambaqué, I., Peters, C., Cowan, M., Harris, R., Blanche, S., Bordigoni, P., Loes, D., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02629-5 · Cited by 329 · cited 5×
“Thus, careful and continuous MRI (and magnetic resonance spectroscopy) examinations (Eichler et al 2002) and neuropsychological tests are the only tools allowing the identification of patients who will benefit from HCT (having MRI changes according to the Loes criteria) (Loes et al 1994a, b).”
BackgroundInfluential
Cited by
Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy
Biffi, A., Montini, E., Lorioli, L., Cesani, M., Fumagalli, F., Plati, T., Baldoli, C., Martino, S., Calabria, A., Canale, S., et al. (2013) · Science · doi:10.1126/science.1233158 · Cited by 1,180
Self-citationPrasad, V. K., Mendizabal, A., Parikh, S. H., Szabolcs, P., Driscoll, T. A., Page, K., Lakshminarayanan, S., Allison, J., Wood, S., Semmel, D., et al. (2008) · Blood · doi:10.1182/blood-2008-03-140830 · Cited by 262
Mucopolysaccharidosis I, II, and VI: brief review and guidelines for treatment
Giugliani, R., Federhen, A., Muñoz Rojas, M. V., Vieira, T., Artigalás, O., Lapagesse Pinto, L., Azevedo, A. C., Acosta, A., Bonfim, C., Lourenço, C. M., et al. (2010) · Genetics and Molecular Biology · doi:10.1590/s1415-47572010005000093 · Cited by 188
“Most of the patients with the severe phenotype which are not submitted to a specific treatment progress to death, on average, before the age of 10 years, due to complications related to brain damage or cardiorespiratory problems (Weisstein et al., 2004; Boelens, 2006).”
BackgroundThe Clinical Outcome of Hurler Syndrome after Stem Cell Transplantation
Aldenhoven, M., Boelens, J., & de Koning, T. J. (2008) · Biology of Blood and Marrow Transplantation · doi:10.1016/j.bbmt.2008.01.009 · Cited by 178
“... for the rapidly progressive CNS involvement in HS patients; 2) Donors with alargernumberofhumanleukocyteantigendisparities can be used, increasing the possibility of finding a suitable donor [51,94]; 3) Despite the higher level of human leukocyte antigen incompatibility, lower rates of acute and chronic graft-vers…”
BackgroundSelf-citationBoelens, J. J., Prasad, V. K., Tolar, J., Wynn, R. F., & Peters, C. (2010) · Pediatric Clinics of North America · doi:10.1016/j.pcl.2009.11.004 · Cited by 109
Self-citationClinical aspects of neuropathic lysosomal storage disorders
Jardim, L. B., Villanueva, M. M., de Souza, C. F. M., & Netto, C. B. O. (2010) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-010-9079-5 · Cited by 34
“…in MPS I Hurler and on late-onset forms of KD and MLD are promising (Krivit et al. 1999; Souillet et al. 2003; Staba et al. 2004 ; Aldenhoven et al. 2008; Peters and Steward 2003; Boelens 2006; Lim et al. 2008; Pierson et al. 2008), showing that lysosomal injuries in the brain are prone to therapy.”
Background
Metadata
- Authors
- Boelens, J. J.
- Venue
- Journal of Inherited Metabolic Disease
- Publisher
- Wiley
- Published
- 2006-04
- Volume
- 29
- Issue
- 2-3
- Pages
- 413-420
- ISSN
- 0141-8955 (ISSN-L)
- 1573-2665
- OpenAlex
- W2064398966
- Cited by
- 111
- References
- 6
- FWCI
- 7.25
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.